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Abstract
Pathologic features of Parkinson’s disease (PD) include death of dopaminergic neurons in the
substantia nigra, presence of α-synuclein containing Lewy bodies, and iron accumulation in PD-
related brain regions. The observed iron accumulation may be contributing to PD etiology but it
also may be a byproduct of cell death or cellular dysfunction. To elucidate the possible role of iron
accumulation in PD, we investigated genetic variation in 16 genes related to iron homeostasis in
three case-control studies from the United States, Australia, and France. After screening 90
haplotype tagging single nucleotide polymorphisms (SNPs) within the genes of interest in the US
study population, we investigated the five most promising gene regions in two additional
independent case-control studies. For the pooled data set (1289 cases, 1391 controls) we observed
a protective association (OR=0.83, 95% CI: 0.71-0.96) between PD and a haplotype composed of
the A allele at rs1880669 and the T allele at rs1049296 in transferrin (TF; GeneID: 7018).
Additionally, we observed a suggestive protective association (OR = 0.87, 95% CI: 0.74-1.02)
between PD and a haplotype composed of the G allele at rs10247962 and the A allele at
rs4434553 in transferrin receptor 2 (TFR2; GeneID: 7036). We observed no associations in our
pooled sample for haplotypes in SLC40A1, CYB561, or HFE. Taken together with previous
findings in model systems, our results suggest that TF or a TF-TFR2 complex may have a role in
the etiology of PD, possibly through iron misregulation or mitochondrial dysfunction within
dopaminergic neurons.
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INTRODUCTION
Brain iron accumulation, beyond that seen in age-matched controls, is frequently observed
in Parkinson’s disease (PD) affected brains (reviewed in (Gerlach et al., 2006)).
Histochemical comparisons of postmortem brain tissue have found increased levels of iron
deposits in the substantia nigra (SN) of parkinsonian brains (Dexter et al., 1987, Sofic et al.,
1991) and specifically in neurons of the SN (Oakley et al., 2007). These pathologic findings
are further supported by magnetic resonance imaging (Gorell et al., 1995, Bartzokis et al.,
1999, Michaeli et al., 2007, Martin et al., 2008) and transcranial ultrasound (Becker et al.,
1995, Walter et al., 2002, Mehnert et al., 2010) studies that observed iron deposits in the SN
in living idiopathic PD patients.
It is debatable whether this accumulation of iron is a cause, co-factor, or consequence of the
dopaminergic (DA) cell death in PD. Iron is a very potent oxidation-reduction agent that can
create oxidative stress in cells and prior work suggests that neurons may be more sensitive to
alterations in iron (Moos et al., 1998, LaVaute et al., 2001) than other cell types in the brain.
Iron is also hypothesized to aggravate some key pathogenic processes related to PD
including alphasynuclein fibril formation (Uversky et al., 2001, Olivares et al., 2009) and
mitochondrial dysfunction (Lin et al., 2001, Horowitz and Greenamyre, 2010). Finally, iron
may simply be a remnant of neuronal cell death (He et al., 2003).
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Animal models provide some potential insight. Genetic knockouts of some iron-related
genes, when not lethal, produce altered brain iron levels (LaVaute et al., 2001, Patel et al.,
2002, Moos and Morgan, 2004). Iron administration to unaltered animals has resulted in
brain iron accumulation (Sengstock et al., 1993) or iron accumulation with a decrease in
dopamine levels (Wesemann et al., 1994, Sziraki et al., 1998). Iron feeding studies in
animals have also observed decreased dopamine levels with a large excess of dietary iron
(Kaur et al., 2007) and with iron in combination with toxins (Levenson et al., 2004, Peng et
al., 2007). These observations suggest that iron is either a cause or a co-factor, not a
consequence, of dopaminergic cells damage, possibly due to the role iron plays in the
synthesis of tyrosine hydroxylase (Snyder and Connor, 2009). Therefore, we hypothesize
that small imbalances in ferrous or ferric brain iron contribute to one or more of the
pathogenic processes contributing to neurodegeneration in PD and propose to investigate
this hypothesis by evaluating the associations between PD and iron-related genes.
To date, epidemiologic studies investigating associations between occupational or dietary
iron exposure and PD have been unpersuasive, and the few reports of iron-related genes and
PD have been predominantly in small studies, investigating rare exonic SNPs, and
inconclusive (reviewed in (Rhodes and Ritz, 2008)). Nevertheless, studies in experimental
models of PD support a role for iron in the etiology or progression of PD (e.g. (Ben-Shachar
and Youdim, 1991, Fredriksson et al., 2001, Kaur et al., 2003)). To facilitate the
investigation of the iron-PD hypothesis, we pooled data from three independent case-control
studies: one each from the United States (US), Australia (AU), and France (FR). All studies
were designed for the investigation of genetic variation; the US and FR studies were also
designed to investigate the influence of pesticide exposure on PD etiology and, therefore,
include subjects with an increased likelihood of exposure to pesticides. In this report, we
present the results from our two-phase study of promoter region, intronic, and exonic SNPs
specifically selected to span each of 16 ironrelated candidate genes and their associations
with PD in a pooled sample of 1286 idiopathic PD cases and 1391 controls.
METHODS
For our two-phase design we screened a larger number of genetic variants in an initial study,
the US Study described below, followed by genotyping of selected variants in two additional
studies based on findings from the initial study. All three studies (Supplemental Table 1)
were pooled for the final analysis.
Studies and Subjects
US Study—The Parkinson’s Environment and Genes (PEG) Study enrolled incident PD
patients with movement disorder specialist confirmed idiopathic PD and population-based
controls between 2001 and 2007 from three counties in the highly agricultural central
California valley of the United States. The recruitment strategy and case definition criteria
have been described in detail elsewhere (Costello et al., 2009, Jacob et al., 2010).
Participants provided either a blood or saliva sample and DNA was extracted by standard
methods. This study was approved by the UCLA Institutional Review Board. At the time of
this investigation, the US Study had enrolled a total of 373 PD cases, but reclassified 13 PD
cases as not idiopathic PD during a follow-up study (Ritz et al., 2012), resulting in a total of
360 idiopathic PD cases and 403 population-based controls available for this investigation.
AU Study—The Australian case-control sample is a subset of the larger Queensland
Parkinson's Project (QPP) Cohort of over 4000 community dwelling individuals recruited to
participate in research into Parkinsonism and related disorders. The recruitment strategy and
inclusion criteria are detailed elsewhere (Sutherland et al., 2009). Only Caucasian subjects
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were included in the study. Patients with PD meeting standard criteria (Gelb et al., 1999)
were recruited from two private and two public movement disorders clinics in Brisbane,
Australia. Control subjects consisted of unaffected electoral roll volunteers, patient spouses,
and community-dwelling unaffected volunteers collected from community groups and
patient neighborhoods. Participants provided blood samples and genomic DNA was
extracted according to standard methods. The study was approved by human research ethics
committees at the Princess Alexandra Hospital, University of Queensland, Royal Brisbane
and Women's Hospital and Griffith University. At the time of this investigation, the AU
study had enrolled 1035 PD cases and 774 controls.
FR Study—This French population-based case-control study was conducted among
subjects enrolled in the Mutualité Sociale Agricole (MSA), the organization responsible for
the reimbursement of health-related expenses to workers in agriculture and has been
described previously (Elbaz et al., 2004, Elbaz et al., 2009, Dutheil et al., 2010). Patients in
62 French districts fulfilling standard criteria (Bower et al., 1999), applying for free health
care for PD for the first time between February 1998 and August 1999, and aged 18–75
years old were enrolled in the study. Population-based controls were recruited among all the
MSA affiliates who requested reimbursement of health expenses between February 1998
and February 2000. A maximum of three controls were matched to each case on age (± 2
years), sex, and region of residency. Participants provided blood samples and genomic DNA
was extracted from peripheral blood leukocytes. The research protocol was approved by the
ethics committee of Hôpital du Kremlin-Bicêtre, and all subjects signed an informed
consent. At the time of this investigation, the FR Study had enrolled a total of 209 PD cases
and 501 population-based controls.
Selection of Genes and SNPs
Candidate genes were selected based on (i) prior reports in studies of PD, (ii) reported
associations from iron-related disorders, and (iii) biologic support for a role in brain iron
homeostasis. Genes were selected prior to publication of the genome-wide association
studies (GWAS) so certain new candidate genes for iron metabolism (e.g. TMPRSS6
(Tanaka et al., 2010))) were not investigated. The 16 selected genes and their role in iron
homeostasis are listed in Table 1. Candidate SNPs were selected from the literature and
haplotype tagging SNPs sufficient to capture the majority of genetic variation in each gene
were selected using Haploview (Barrett et al., 2005). Some candidate SNPs, e.g. H63D in
HFE, were not available on the platform used for the initial phase of genotyping and
therefore were not investigated. In total 90 SNPs in 16 genes were genotyped in the US
Study.
Genotyping Methods
Phase 1, US Study—Of the 360 PD cases and 403 population-based controls in the US
Study, We genotyped 356 cases and 375 controls with available DNA for 90 SNPs using the
Illumina Goldengate assay. In total 6 of 90 SNPs failed genotyping or were homozygous in
the population: rs2075674 and rs7786877 in TFR2, rs11709714 in CP, rs1535921 in HFE2,
and rs4428180 in TF failed genotyping and rs2858996 in HFE was homozygous in the US
Study population. Therefore, we evaluated 84 SNPs across 15 of 16 genes (only one SNP
was genotyped in HFE2 and that SNP failed) in this first phase. We limited the first phase
analyses to those subjects with a genotyping success rate of at least 90% resulting in 347
cases and 360 controls contributing to this investigation.
Phase 2, AU and FR Studies—We genotyped 20 SNPs in 1035 cases and 774 controls
from the AU Study and genotyped 17 SNPs in 209 cases and 501 controls from the FR
Study selected based on results from phase 1. Discrepancies in the number of tagSNPs
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genotyped were due to budget limitations requiring priority given to different candidate
genes by the respective Principle Investigators. Genotyping was performed using the
Sequenom iPLEX platform (AU Study) and the Illumina Goldengate assay (FR Study). We
limited the second phase analyses to those subjects with a genotyping success rate of at least
96% resulting in 739 cases and 538 controls from the AU Study and 203 cases and 493
controls from the FR Study contributing to this investigation.
Statistical Methods
The 84 SNPs genotyped in the US study that passed quality assessment were screened for
differences in allele frequency between case and controls. These 84 SNPs within 15 genes
captured the genetic variation across 31 regions or haplotype blocks (Daly et al., 2001, Wall
and Pritchard, 2003, Crawford and Nickerson, 2005). The number of regions exceeds the
number of genes because many genes contained more than one region of high linkage
disequilibrium; for example, transferrin (TF) contains three regions. The regions that
contained one or more SNPs with a screening p-value less than 0.20 were further assessed in
the US study using haplotypes constructed in PLINK (Purcell et al., 2007). We then
evaluated association with PD for these haplotype block regions using an unconditional
logistic regression model adjusted for age (continuous), sex (male/female), and race (CA/
non-CA) for association with PD. Finally, the block regions that contained at least one
haplotype with a p-value less than 0.15 were considered for investigation in all three studies
combined. The pooled analysis was performed using unconditional logistic regression
adjusted for age (continuous), sex (male/female), race (Caucasian/non-Caucasian), and study
(US/AU/FR). Two sensitivity analyses were performed. First, the pooled analysis was
performed excluding non-Caucasian subjects from the US Study. Second, the pooled
analysis was performed using the haplo.stats R package (version 1.5.0) which implements
probability weighting to account for ambiguity in the inferred haplotype (Schaid et al., 2002,
Sinnwell and Schaid, 2011).
RESULTS
Phase 1, Screening in US Study
From the 84 SNPs screened in the US Study (phase 1; Supplementary Table 2), 12 out of 31
regions (haplotype blocks) contained one or more SNPs with a sufficient screening p-value
for consideration in the phase 1 haplotype analysis. These 12 regions were in 10 of the 15
genes evaluated in the US Study: FRRS1, SLC40A1, TF (2 regions), CP (2 regions), HFE,
TFR2, IREB2, CYB561, FECH, and HAMP (no SNPs in LTF, TFRC, FTMT, SLC11A2, and
HEPH met the screening criterion). In the haplotype analysis of the US Study
(Supplementary Table 3), seven of those 12 regions met the p-value criteria for investigation
in the combined US/AU/FR sample.
The seven regions, identified by the screening analysis in the US study, were located in
seven independent genes and were defined by 19 SNPs. A priori, the FECH region was not
chosen to be of interest in the two phase 2 study samples (AU/FR) and so we are unable to
follow up on it. Additionally, we could only consider a single SNP for the region located in
CP (rs701754, which tags the risk haplotype observed in the US study) and only using the
US and FR studies; we found no association for that single SNP in the two studies combined
(OR=1.09, 95%CI: 0.88-1.35). Overall, we evaluated five regions located in five
independent genes and defined by 11 SNPs in the combined US/AU/FR Study population.
Phase 2, Pooled Analysis in US/AU/FR Studies
We observed a protective association (OR=0.83, 95% CI: 0.71-0.96) between PD and a
haplotype in the transferrin gene (TF; GeneID: 7018) comprised of the A allele at
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rs1880669 and the T allele at rs1049296 in the pooled anlaysis (Table 2). When considering
each study individually, we observed very similar magnitude odd ratios in all three
populations. Analyses excluding the non-Caucasians from the US study did not alter the
pooled odds ratio or the individual US study association.
Additionally, in the pooled sample, we observed a suggestive protective association
(OR=0.87, 95% CI: 0.73-1.02) between PD and a haplotype in the transferrin receptor 2
gene (TFR2; GeneID: 7036) comprised of the G allele at rs10247962 and the A allele at
rs4434553. When considering each study individually, we observed this association
predominantly in the US study; the FR study demonstrated only a weakly suggestive
association (OR=0.88) and the AU study demonstrated no association (OR=1.00).
Analyses excluding the non-Caucasians from the US study did not alter the pooled odds
ratio or the individual US study association. Analysis accounting for the posterior
probability of the inferred haplotypes resulted in nearly identical effect estimates and
confidence intervals in the pooled sample (Supplementary Table 4).
DISCUSSION
Based on the well-documented accumulation of iron in the substantia nigra (SN) of
Parkinson’s disease (PD) brains we pursued a hypothesis generating effort investigating
genetic variants of iron-related genes for association with PD. Our results are intriguing and
suggest of a role for genetic variants in transferrin and transferrin receptor 2 in the etiology
or pathology of PD. While these findings must be considered exploratory, we observed a
15–20% decrease in risk of PD for subjects with genetic variation in the TF gene suggesting
that if variation in the TF gene impacts iron import, storage, transport, or export in
dopaminergic neurons then iron accumulation in PD brains may be a cause, not a
consequence of neuronal cell death.
The functional consequences of any causal variant(s) captured by our haplotype block
within the TF gene (a 46kb length including exons 9–17 and the 3’ UTR) are unknown.
Genetic variants in the promoter and G277S (rs1799899) in exon 7 have been investigated
for association with iron-related measures with equivocal results (Lee et al., 2001, Aisen,
2003, Delanghe et al., 2006, Sarria et al., 2007). In contrast, recent GWAS findings
consistently report an increase in serum transferrin levels (or total iron binding capacity
(TIBC), a proxy for serum transferrin) associated with the minor allele of rs3811647 in
intron 11 of TF. This association appears to be independent of race/ethnicity, gender,
menstruation status, or diet (Benyamin et al., 2009a, Benyamin et al., 2009b, Blanco-Rojo et
al., 2011, McLaren et al., 2011, Traglia et al., 2011, McLaren et al., 2012). Benyamin et al
(2009a) and Blanco-Rojo (2011) report borderline associations between rs3811647 and
transferrin saturation, and none of the studies observed an association between rs3811647
and serum iron or serum ferritin. The association between TF rs3811647 and serum
transferrin, but lack of association with other measures of iron status, suggests a role for TF
in serum transferrin levels independent of total body iron metabolism (McLaren et al.,
2011).
We observed no association between genetic variation in the HFE gene and PD in our
pooled analysis. Considering the C282Y (rs1800562) variant alone, the US study observed
no association (OR=0.91, 95%CI: 0.59-1.41) and the FR Study has not published on this
variant. The AU Study had previously published an association between C282Y and PD
(Buchanan et al., 2002) but this was on an early, smaller set of subjects. The C282Y variant
of HFE is associated with serum transferrin levels (Benyamin et al., 2009a, Benyamin et al.,
2009b, Blanco-Rojo et al., 2011, McLaren et al., 2011, Traglia et al., 2011), and associated
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with transferrin saturation and serum iron levels in some studies (Benyamin et al., 2009b,
Traglia et al., 2011) but not others (Blanco-Rojo et al., 2011, McLaren et al., 2011). The
H63D (rs1799945) variant, which we were unable to assess in our study populations and is
not investigated in most of the GWAS, may (Blanco-Rojo et al., 2011) or may not
(Whitfield et al., 2000) be associated with serum transferrin levels, but is associated with
serum iron and transferrin saturation in the one study reporting on that variant (Whitfield et
al., 2000). Our lack of observed associations between PD and genetic variation in
hemochromatosis (HFE) or hepcidin (HAMP), both proteins with recognized roles in
systemic iron regulation (Ezquerra et al., 2005, Benyamin et al., 2009a, Drakesmith and
Prentice, 2012), support a hypothesis that the pathologic role of iron in PD could be
unrelated to systemic iron homeostasis.
The TF haplotype associated with a decreased risk of PD in this pooled analysis does not
contain the minor (A) allele of rs3811647 observed to be associated with increased serum
transferrin/TIBC levels in GWAS; our associated haplotype contains the major allele (G) at
this locus. This could suggest that the protection against PD conferred by the AT haplotype
of rs1880669-rs1049296 is related to non-elevated serum transferrin/TIBC levels, an
unlikely hypothesis given that PD affects fewer than 1% of the population and normal serum
transferrin/TIBC levels are observed in the vast majority of the general population.
Alternatively, our protective TF haplotype could be influencing PD etiology through
alterations in regulation, structural changes in the protein, modifications to the iron binding
affinity of the transferrin protein, or biologic interactions of the transferrin protein with other
cellular proteins.
The transferrin protein is a glycoprotein with homologous carboxyl and amino domains,
each binding one ion of ferric iron (MacGillivray et al., 1982) that transports iron through
the extracellular environment. Transferrin is the primary receptor-mediated transporter of
iron across the blood brain barrier (Moos et al., 2007) and a transporter of iron throughout
the brain. Oligodendrocytes are the primary source of transferrin protein for the brain (Zecca
et al., 2004, Rouault et al., 2009) and the location of most brain iron due to its use in
mylenation (Todorich et al., 2009), but iron has been detected in dopaminergic neurons and
even co-localizes with dopamine in vesicles (Ortega et al., 2007). Transferrin receptor, the
primary binding site for transferrin and facilitator of iron transport into most cells, is found
at very low concentrations in the substantia nigra pars compacta (SNpc) and on SN
dopaminergic (DA) neurons (Faucheux et al., 1993, Morris and Edwardson, 1994,
Mastroberardino et al., 2009) suggesting an alternative method of iron import into
dopaminergic neurons, which may further suggest that our association between PD and TF
is due to actions of transferrin unrelated to the transport of iron into dopaminergic neurons.
We observed a suggestive association between PD and transferrin receptor 2 (TFR2), a
protein that has been detected on SNpc DA neurons, but not on SN pars reticulata neurons
or astrocytes and microglia in the SN brain region (Mastroberardino et al., 2009). This
suggests that iron transport in to SNpc DA neurons might be mediated through a TF-TFR2
complex. Furthermore, TFR2 proteins have been detected on mitochondria of DA neurons
implying a possible link between iron accumulation, oxidative stress, and mitochondrial
dysfunction.
This TF-TFR2 mediated mitochondrial mechanism of pathology is likely to be only one of a
number of factors contributing to PD pathology. Given that iron excess (or iron depletion) in
models systems aggravates (or attenuates) pesticide toxicity (e.g., (Kaur et al., 2003, Peng et
al., 2007), it is possible that genetic susceptibility to iron mishandling combined with
pesticide exposure contributes to the etiology of PD, for example through increased
oxidative stress and mitochondrial dysfunction. Of note, two of the three studies in this
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report were designed to investigate the contributions of pesticides to PD and therefore
enrolled subjects with a higher likelihood of pesticide exposure than many other studies of
PD. Our heightened level of pesticide exposure might explain why prior studies of PD and
TF genetic variation, particularly the GWAS studies of PD, do not detect associations. The
lack of pesticide exposure in the AU study might also explain why the TFR2 finding is
closer to null in that study population.
Mitochondrial dysfunction and oxidative stress are two highly interrelated pathogenic
hypotheses implicated in PD etiology. Our epidemiologic research and the basic science
research of others (e.g., (Kaur et al., 2007, Mastroberardino et al., 2009)) suggest that iron
accumulation may also be a pathogenic mechanism pertinent to PD etiology. In addition to
the role iron might have in mitochondrial dysfunction and oxidative stress, iron may
aggravate inhibition of the ubiquitin-proteasome system (Zhang et al., 2005) and may
contribute to alpha-synuclein aggregation (Uversky et al., 2001) or overexpression
(Febbraro et al., 2012). The toxicity of paraquat, a pesticide that has been associated with
PD (Costello et al., 2009), is increased by excess iron (Andersen, 2003) and iron chelation
can mediate toxin induced cell death (Kaur et al., 2003, Jimenez-Del-Rio et al., 2010).
PD is recognized as a disease of complex etiology (Vance et al., 2010) and our findings lend
credence to the continued investigation of iron accumulation as a causal contributor to PD.
In particular, our findings of an association between PD and transferrin genetic variation, as
well as the suggestive association with transferrin receptor 2 genetic variation, encourage
further elucidation of iron transport mechanisms in dopaminergic neurons and their
mitochondria.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
• 16 iron homeostasis genes were considered for association with Parkinson’s
disease
• Data from 3 case-control studies (United States, Australia, and France) were
pooled
• 3’ region of transferrin (TF) was associated with PD (OR=0.83 [0.71–0.96])
• Transferrin receptor 2 (TFR2) genetic variation may also be associated with PD
• TF-TFR2 findings suggest roles for iron misregulation or mitochondrial
dysfunction
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Table 1
Iron-related Genes Investigated
Gene id Location Symbol Gene Name
391059 1p21.2 FRRS1 ferric-chelate reductase 1
function: ferric reductase
148738 1q21.1 HFE2 hemochromatosis type 2
function: hepcidin regulation
30061 2q32 SLC40A1 solute carrier family 40, member 1
function: iron export from cells
4057 3p21.31 LTF lactotransferrin
function: iron binding and transport
7018 3q22.1 TF transferrin
function: iron binding and transport
1356 3q23-q25 CP ceruloplasmin
function: peroxidation of Fe2+transferrin to Fe3+ transferrin
7037 3q29 TFRC transferrin receptor
function: transferrin endocytosis and recycling
94033 5q21.3 FTMT mitochondrial ferritin
function: iron binding and oxidation
3077 6p21.3 HFE hemochromatosis
function: regulate iron absorption
7036 7q22 TFR2 transferrin receptor 2
function: mediates cellular uptake of transferrin-bound iron
4891 12q13 SLC11A2 solute carrier family 11, member 2
function: iron absorption and transport of divalent metals
3658 15q25.1 IREB2 iron-responsive element binding protein 2
function: protein regulation via iron-responsive elements
1534 17q23.3 CYB561 cytochrome b561
function: ferric reductase
2235 18q21.3 FECH ferrochelatase
function: catalyze the insertion of iron into heme
57817 19q13.1 HAMP hepcidin antimicrobial peptide
function: regulation of iron storage
9843 Xq11-q12 HEPH hephaestin
function: iron transport
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